乙型肝炎肝硬化癌变患者病毒标志物及DNA检测

Detection of HBV Immunological Markers and DNA in Patients with Canceration of Posthepatic Cirrhosis by HBV

目的通过对乙型肝炎病毒标志物及DNA的检测,探讨其在肝硬化癌变进程中所起的作用。方法采用实时荧光定量聚合酶链反应(FQ-PCR)对52例乙型肝炎肝硬化癌变和68例肝硬化血清中HBV DNA含量进行检测,同时用ELISA法检测其HBV免疫标志物。结果乙型肝炎肝硬化癌变及肝硬化中HBsAg、HBeAb、HBcAb和HBV DNA的阳性率均较高,而HBsAb阳性率较低;HBsAg在乙型肝炎肝硬化癌变中阳性率低于肝硬化(P<0.05),分别为21.2%和39.7%。结论乙型肝炎肝硬化癌变及肝硬化患者均存在着HBV的持续复制,HBeAg的变异可能在肝细胞癌变过程中起着一定的作用。

Objective The aim of this study was to evaluate the role of HBV in cancerization of posthepatic cirrhosis by detecting HBV immunological markers and DNA. Methods HBV immunological markers of 52 patients with cancerization of posthepatic cirrhosis and 68 cases with posthepatic cirrhosis were detected by fluorescent quantitation polymerase chain reaction （FQ-PCR） and HBV DNA of these patients by ELISA assay. Results The positive rates of HBsAg, HBeAb, HBcAb and HBV DNA all were high in patients with cancerization of posthepatic cirrhosis and posthepatic cirrhosis, but the positive rate of HBsAb was low. The positive rate of HBeAg in patients with cancerization of posthepatic cirrhosis was lower than that of posthepatic cirrhosis （P 〈 0.05 ） , they were 21.2% and 39.7% respectively. Conclusions HBV persistently replicates in patients with cancerization of posthepatic cirrhosis and posthepatic cirrhosis. Variation of HBeAg might play an important role in cancerization of hepatic cells.